Active Filter(s):
Details:
The publication reports that trigeminal pain pathway activation is significantly reduced after intranasal IGF-1 treatment.
Lead Product(s): Human Insulin-Like-Growth-Factor-I 21-40
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2020